💥Descubre en 30 segundos quiénes somos y qué es lo que hacemos.

Y recuerda si eres médico o especialista en #Feo #Para o #CarcinomaSuprarrenal recomiéndanos a tus pacientes para que sepan que no están solos 🙏

#Net #enfermedadesraras

youtu.be/TNUJsieMHaY?si…

🚨 A new study looking at TKI+IO in NETs. Results similar to the Grupo GETNE CABATEN study (ORR 0% in Lung NETs and 16.7% in GI-NETs although G1 and G2). It seems that the combination is not better than TKI in monotherapy. What are your impressions❓🤔

An honour to present the data from the DUTHY trial at the European Society of Neuroendocrine Tumours #ENETS24 .
🥇The first data to date on the efficacy of immunotherapy in medullary thyroid carcinoma. Grupo GETNE 👇👇👇👇

Thank you very much Jaume Capdevila for your confidence and support. You are a reference and mentor for me. Without you and J Hernando all this would not be possible. My successes are also yours!

Felicidades Nadia Saoudi González! Más que merecido. Feliz de ver tus éxitos hechos realidad. Te echaremos de menos...😞

It is important to have representation of all tumours in pan-cancer biomarker studies. Rare tumours are included (e.g. ACC), but what about neuroendocrine tumours? #LetsTalkAboutNETs Grupo GETNE NET- ESPAÑA NET CONNECT NANETS

After many other TKIs, positive results of Cabozantinib in pancreatic and extra-pancreatic NETs. But the questions are 🤔: Will we see a new TKI in the guidelines? Will it get approval in Europe?👇👇👇

Join us EMBL Barcelona! We a looking for a new Head of Administration. We are seeking a brilliant operational mind to partner with brilliant science.

Closing date: 13 September
please reach out if you have questions.
embl.org/jobs/position/…
RT appreciated

3rd day #WCGIC2023 🤩🤩 …. Amazing presentations!!!! 🔝🔝
✅Poster day: Clinicopathological and molecular features of two rara entities: Appendiceal Carcinoma and Small Bowel ADK
Many thanks to the authors Sergio Bueno Alejandro Garcia J Hernando Jaume Capdevila
#ResisOncoVH
Vall d’Hebron Institute of Oncology (VHIO)

#ASCO23
Estudio fase I 1438-0001
BI 764532 (biespecífico DLL3/CD3) en SCLC y NEC extrapulmonar DLL3➕️
Datos de eficacia preliminares:

n=107 (41 epNEC)
ORR 25% (19% epNEC)

Actualmente abierto a reclutamiento en varios centros en 🇪🇦
clinicaltrials.gov/ct2/show/NCT04…

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022) | SpringerLink ⁦⁦Grupo GETNE⁩ ⁦SEOM⁩ ⁦Vall d’Hebron Institute of Oncology (VHIO)⁩ ⁦Vall d'Hebron⁩ link.springer.com/article/10.100…

Hoy tenemos una cita con los Tumores Neuroendocrinos en Barcelona! Pero si no puedes estar, también hay modalidad online.

Las últimas novedades clínicas y trasacionales del último congreso de la ENETS aquí! 👇👇👇👇👇👇👇

Grupo GETNE Jaume Capdevila J Hernando @adacap_news

Excited to announce the publication of our article in #EJC ‼️ ScienceDirect

📢 'Sex differences on MKI toxicity in patients with advanced GEP NETs' 🩺

Applying a gender perspective to cancer research is both possible and necessary. Vall d’Hebron Institute of Oncology (VHIO) Grupo GETNE
doi.org/10.1016/j.ejca…

Aprendiendo de neoplasias neuroendocrinas con el mejor equipo!!!😄😄😄🤩

Alejandro Garcia Jaume Capdevila J Hernando

Lenvatinib + Pembrolizumab in thoracic and intestinal NETs. ORR 10% and PFS 9 months (in TALENT with Lenvatinib in G1-2 sbNETs ORR 16% and PFS 15.6 months). Influence on dose of 20mg Lenvatinib (vs 24mg in TALENT)? Great presentation by Dr. Strosberg at #ENETS23 Grupo GETNE

True teamwork‼️

Our projects at Grupo GETNE and @vhio mentioned together in a couple slides in the excellent presentation about Lung NETs by Jaume Capdevila